2014
How can mathematical models advance tuberculosis control in high HIV prevalence settings?
Houben RM, Dowdy DW, Vassall A, Cohen T, Nicol MP, Granich RM, Shea JE, Eckhoff P, Dye C, Kimerling ME, White RG, . How can mathematical models advance tuberculosis control in high HIV prevalence settings? The International Journal Of Tuberculosis And Lung Disease 2014, 18: 509-514. PMID: 24903784, PMCID: PMC4436821, DOI: 10.5588/ijtld.13.0773.Peer-Reviewed Original ResearchConceptsHigh HIV prevalence settingsHIV prevalence settingsTB-HIVTuberculosis controlPrevalence settingsHigh human immunodeficiency virus (HIV) prevalenceHuman immunodeficiency virus (HIV) prevalenceTB ModellingHealth policy makersDifficult diagnosisDisease progressionHigh riskHigh mortalityHealth systemNatural progressionVirus prevalencePublic healthProgressionMortalityPrevalenceSettingAnalysis ConsortiumDiagnosisExpert discussion
2006
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV–tuberculosis coinfected populations
Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV–tuberculosis coinfected populations. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 7042-7047. PMID: 16632605, PMCID: PMC1459015, DOI: 10.1073/pnas.0600349103.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyDrug-resistant TBCommunity-wide isoniazid preventive therapyPreventive therapyTuberculosis infectionTB controlLatent Mycobacterium tuberculosis infectionLatent tuberculosis infectionProportion of patientsMycobacterium tuberculosis infectionIncidence of TBTuberculosis case notificationCommunity-wide implementationEmergence of HIVCommunity-wide strategiesHIV-tuberculosisTB-HIVCoinfected individualsTB epidemicCase notificationTreatment policyHIVTherapyInfectionTB